[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:grpr-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"GRPR Gene",4,2,[8,16,22,29],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05283330","Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:16:40.941792Z","2026-05-05T02:43:28.512355Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07114601","A Study of LY4257496 in Participants With Cancer (OMNIRAY)",[12],"2026-08-26T02:15:22.311223Z","2026-07-05T05:32:16.734287Z",{"nct_id":23,"title":24,"phases":25,"status":26,"updated_at":27,"content_modified":28},"NCT05870579","[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T01:56:19.375288Z","2026-05-05T02:43:29.159903Z",{"nct_id":30,"title":31,"phases":32,"status":26,"updated_at":34,"content_modified":35},"NCT06247995","A Phase I\u002FII, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4\u002F6 Inhibitor.",[33],"Phase 1\u002FPhase 2","2026-08-03T02:28:08.200434Z","2026-05-05T02:43:26.930244Z"]